Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak

January 12, 2023 updated by: Yale-NUS College
This study aims to evaluate the mental health impact of the COVID-19 pandemic on international migrant workers by (1) documenting mental health symptoms among migrant workers and (2) identifying risk and protective factors during the pandemic.

Study Overview

Status

Completed

Conditions

Detailed Description

Worldwide, there are an estimated 164 million migrant workers. Although studies have documented how migrant workers have an increased risk of adverse mental health outcomes, little is known about their mental health burden during a large-scale health crisis.

In the current COVID-19 outbreak, migrant workers represent 9 in 10 of the COVID-19 cases in Singapore, with 25 dormitories gazetted to contain the spread of the virus. Correspondingly, these measures have placed a spotlight on the mental well-being of migrant workers.

In this research protocol, the investigators propose to administer a survey to understand the prevalence and predictors of mental health symptoms amongst migrant workers in Singapore. In particular, prior meta-analyses have identified COVID-19 health concerns, quarantine status, financial instability, exposure to news and misinformation and demographics (i.e., gender, age, education) as risk factors for poor mental health amongst the general population. By assessing these factors amongst the migrant worker population and documenting their impact on migrant workers' mental health, we hope to identify workers in greatest need of support during the ongoing pandemic and provide empirical evidence to guide public health policies.

Study Type

Observational

Enrollment (Actual)

1011

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Migrant workers employed in manual labor jobs within Singapore

Description

Inclusion Criteria:

  • ≥21 years of age
  • Hold a government-issued work permit identifying employment status

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
DASS-21 Scores
Time Frame: single measurement upon study enrolment
Depression, Anxiety and Stress Scale (DASS-21) is a validated 21-item measure that has been widely used during the current COVID-19 pandemic.
single measurement upon study enrolment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 22, 2020

Primary Completion (Actual)

October 11, 2020

Study Completion (Actual)

October 11, 2020

Study Registration Dates

First Submitted

June 25, 2020

First Submitted That Met QC Criteria

June 25, 2020

First Posted (Actual)

June 26, 2020

Study Record Updates

Last Update Posted (Estimate)

January 13, 2023

Last Update Submitted That Met QC Criteria

January 12, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • CCF@EXPO/R001/2020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Health Issue

3
Subscribe